Stemness features in liver cancer

Abstract

Heterogeneity is a cardinal hallmark of cancer, including primary liver cancer (PLC), and occurs at different layers including putative cell-of-origin. Current evidence suggests that within cellular subpopulations in PLC there are stem-like cells, the cancer stem cells (CSCs). The CSC concept has been recently proposed as an explanation of such intra-tumor heterogeneity. According to this model, CSCs are responsible for tumor initiation, recurrence, metastasis as well as drug-resistance. However, although the CSC hypothesis is intriguing and supported by a large number of experimental studies, there are still open questions regarding the origin of putative CSCs. Since chemo-resistance and recurrence represent major issues in PLC treatment, the development of new therapeutic strategies is needed, for which a good understanding of tumor behavior and in particular of CSCs biology is an imperative prerequisite. In this review we summarize the regulatory pathways that support CSC features in PLC. Moreover, we highlight the key features of hepatic CSC, in terms of enhanced drug-resistance, increased metastatic potential and metabolic rearrangement. Knowledge of the molecular mechanisms underlying CSC biology may provide novel options for PLC combination therapies.

Keywords

Hepatocellular carcinoma / cholangiocarcinoma / cancer stem cells / tumor heterogeneity / drug-resistance

References

[1] El-Serag HB.Hepatocellular carcinoma..N Engl J Med2011;365:1118-27

[2] Oikawa T.Cancer stem cells and their cellular origins in primary liver and biliary tract cancers..Hepatology2016;64:645-51

[3] Kumar M,Wang XW.Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?.Cell Biosci2011;1:5 PMCID:PMC3116244

[4] Shaib Y.The epidemiology of cholangiocarcinoma..Semin Liver Dis2004;24:115-25

[5] Banales JM,Carpino G,Andersen JB.Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)..Nat Rev Gastroenterol Hepatol2016;13:261-80

[6] Machida K.Existence of cancer stem cells in hepatocellular carcinoma: myth or reality?.Hepatol Int2017;11:143-7 PMCID:PMC5759320

[7] Sia D.Liver cancer: translating ‘-omics’ results into precision medicine for hepatocellular carcinoma..Nat Rev Gastroenterol Hepatol2017;14:571-2

[8] Bruix J,Gores G,Mazzaferro V.Liver cancer: approaching a personalized care..J Hepatol2015;62:S144-56 PMCID:PMC4520430

[9] Lohitesh K,Mukherjee S.Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight..Cancer Cell Int2018;18:44 PMCID:PMC5859782

[10] Lu LC,Hsu C.Tumor Heterogeneity in hepatocellular carcinoma: facing the challenges..Liver Cancer2016;5:128-38 PMCID:PMC4906428

[11] Andersen JB,Blechacz BR,Komuta M.Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors..Gastroenterology2012;142:1021-31.e15 PMCID:PMC3413201

[12] Blechacz B.Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment..Hepatology2008;48:308-21 PMCID:PMC2547491

[13] Rizvi S.Pathogenesis, diagnosis, and management of cholangiocarcinoma..Gastroenterology2013;145:1215-29 PMCID:PMC3862291

[14] Zabron A,Khan SA.The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer..Dis Model Mech2013;6:281-92 PMCID:PMC3597011

[15] Khan SA,Davidson BR.Cholangiocarcinoma..Lancet2005;366:1303-14

[16] Blechacz B,Roskams T.Clinical diagnosis and staging of cholangiocarcinoma..Nat Rev Gastroenterol Hepatol2011;8:512-22 PMCID:PMC3331791

[17] Govaere O,Petz M,Van den Eynde K.Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche..J Hepatol2016;64:609-17

[18] Berthiaume EP.The molecular pathogenesis of cholangiocarcinoma..Semin Liver Dis2004;24:127-37

[19] Komuta M,Vander Borght S,Verslype C.Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin..Hepatology2008;47:1544-56

[20] Lee JS,Libbrecht L,Kaposi-Novak P.A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells..Nat Med2006;12:410-6

[21] Nomoto K,Cheng C,Hori R.Intrahepatic cholangiocarcinoma arising in cirrhotic liver frequently expressed p63-positive basal/stem-cell phenotype..Pathol Res Pract2006;202:71-6

[22] Yamashita T,Budhu A,Yang W.EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features..Gastroenterology2009;136:1012-24 PMCID:PMC2828822

[23] Zhou H,Zhou D,Zou S.Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis..Eur J Cancer2010;46:1056-61

[24] Brunt E,Clavien PA,Goodman Z.cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation..Hepatology2018;68:113-26

[25] Sato K,Meng F,Glaser S.Ductular reaction in liver diseases: pathological mechanisms and translational significances..Hepatology2018;

[26] Gouw AS,Theise ND.Ductular reactions in human liver: diversity at the interface..Hepatology2011;54:1853-63

[27] Kuwahara R,Landis CS,Barendswaard E.The hepatic stem cell niche: identification by label-retaining cell assay..Hepatology2008;47:1994-2002 PMCID:PMC2847183

[28] Theise ND,Portmann BC,Yee H.The canals of Hering and hepatic stem cells in humans..Hepatology1999;30:1425-33

[29] Roskams T.Liver stem cells and their implication in hepatocellular and cholangiocarcinoma..Oncogene2006;25:3818-22

[30] Kitade M,Andersen JB,Kaji K.Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling..Genes Dev2013;27:1706-17 PMCID:PMC3744728

[31] Raggi C,Andersen JB.Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts..J Hepatol2015;62:198-207

[32] Woo HG,Yoon JH,Lee HS.Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma..Cancer Res2010;70:3034-41 PMCID:PMC3498758

[33] Zhang F,Zhang W,Xiang S.Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence..Histopathology2008;52:224-32

[34] Sia D,Moeini A.Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies..Oncogene2013;32:4861-70 PMCID:PMC3718868

[35] Cardinale V,Reid L,Alvaro D.Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity..World J Gastrointest Oncol2012;4:94-102 PMCID:PMC3360107

[36] Andersen JB.Genetic profiling of intrahepatic cholangiocarcinoma..Curr Opin Gastroenterol2012;28:266-72 PMCID:PMC4017233

[37] Carpino G,Onori P,Berloco PB.Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages..J Anat2012;220:186-99 PMCID:PMC3275774

[38] Razumilava N.Notch-driven carcinogenesis: the merging of hepatocellular cancer and cholangiocarcinoma into a common molecular liver cancer subtype..J Hepatol2013;58:1244-5 PMCID:PMC3818720

[39] Zucman-Rossi J,Zender L.Primary liver carcinomas can originate from different cell types: a new level of complexity in hepatocarcinogenesis..Gastroenterology2013;145:53-5

[40] Raggi C,Correnti M,Invernizzi P.Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies..Oncogene2016;35:671-82

[41] Holczbauer A,Andersen JB,Kleiner DE.Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types..Gastroenterology2013;145:221-31 PMCID:PMC3913051

[42] Fan B,Calvisi DF,Razumilava N.Cholangiocarcinomas can originate from hepatocytes in mice..J Clin Invest2012;122:2911-5 PMCID:PMC3408746

[43] Sekiya S.Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes..J Clin Invest2012;122:3914-8 PMCID:PMC3484442

[44] Fidler IJ.Biological diversity in metastatic neoplasms: origins and implications..Science1982;217:998-1003

[45] Heppner GH.Tumor heterogeneity: biological implications and therapeutic consequences..Cancer Metastasis Rev1983;2:5-23

[46] Kreso A.Evolution of the cancer stem cell model..Cell Stem Cell2014;14:275-91

[47] Beachy PA,Berman DM.Tissue repair and stem cell renewal in carcinogenesis..Nature2004;432:324-31

[48] Clarke MF,Dirks PB,Jamieson CH.Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells..Cancer Res2006;66:9339-44

[49] Morrison SJ.Asymmetric and symmetric stem-cell divisions in development and cancer..Nature2006;441:1068-74

[50] Plaks V,Werb Z.The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?.Cell Stem Cell2015;16:225-38 PMCID:PMC4355577

[51] Boesch M,Zeimet AG,Gastl G.Heterogeneity of cancer stem cells: rationale for targeting the stem cell niche..Biochim Biophys Acta2016;1866:276-89 PMCID:PMC5818142

[52] Yamashita T.Cancer stem cells in the development of liver cancer..J Clin Invest2013;123:1911-8 PMCID:PMC3635728

[53] Mani SA,Liao MJ,Ayyanan A.The epithelial-mesenchymal transition generates cells with properties of stem cells..Cell2008;133:704-15 PMCID:PMC2728032

[54] O’Brien CA,Gallinger S.A human colon cancer cell capable of initiating tumour growth in immunodeficient mice..Nature2007;445:106-10

[55] Borovski T,Vermeulen L.Cancer stem cell niche: the place to be..Cancer Res2011;71:634-9

[56] Ma S,Zheng BJ,Guan XY.CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway..Oncogene2008;27:1749-58

[57] Pattabiraman DR.Tackling the cancer stem cells - what challenges do they pose?.Nat Rev Drug Discov2014;13:497-512 PMCID:PMC4234172

[58] da Silva-Diz V,Bernat-Peguera A,Munoz P.Cancer cell plasticity: impact on tumor progression and therapy response..Semin Cancer Biol2018;

[59] Virchow R.An address on the value of pathological experiments..Br Med J1881;2:198-203 PMCID:PMC2264055

[60] Sainz B, Jr.,Vallespinos M.Cancer stem cells and macrophages: implications in tumor biology and therapeutic strategies..Mediators Inflamm2016;2016:9012369 PMCID:PMC4769767

[61] Rais Y,Geula S,Chomsky E.Deterministic direct reprogramming of somatic cells to pluripotency..Nature2013;502:65-70

[62] Chaffer CL,Scheel C,Wiggins PA.Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state..Proc Natl Acad Sci U S A2011;108:7950-5 PMCID:PMC3093533

[63] Wang JC.Cancer stem cells: lessons from leukemia..Trends Cell Biol2005;15:494-501

[64] Cheng L,Flesken-Nikitin A,Nikitin AY.Mouse models for cancer stem cell research..Toxicol Pathol2010;38:62-71 PMCID:PMC2827660

[65] Marquardt JU,Andersen JB,Avital I.Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways..Hepatology2011;54:1031-42 PMCID:PMC3179780

[66] Ma S,Hu L,Wo JY.Identification and characterization of tumorigenic liver cancer stem/progenitor cells..Gastroenterology2007;132:2542-56

[67] Raggi C,Seo D,Gillen MC.Epigenetic reprogramming modulates malignant properties of human liver cancer..Hepatology2014;59:2251-62 PMCID:PMC4043911

[68] Yamashita T,Wang W,Ye Q.EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma..Cancer Res2008;68:1451-61

[69] Hsieh A,Lim SO,Jung G.Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/beta-catenin signaling..Cancer Lett2011;300:162-72

[70] Raggi C,Sica A,Cardinale V.Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages..J Hepatol2017;66:102-15 PMCID:PMC5522599

[71] Kokuryo T,Nagino M.Recent advances in cancer stem cell research for cholangiocarcinoma..J Hepatobiliary Pancreat Sci2012;19:606-13

[72] Takahashi K.Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors..Cell2006;126:663-76

[73] Schoenhals M,De Vos J,Moreaux J.Embryonic stem cell markers expression in cancers..Biochem Biophys Res Commun2009;383:157-62

[74] Ben-Porath I,Carey VJ,Bell GW.An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors..Nat Genet2008;40:499-507 PMCID:PMC2912221

[75] Jeter CR,Choy G,Patrawala L.Functional evidence that the self-renewal gene NANOG regulates human tumor development..Stem Cells2009;27:993-1005 PMCID:PMC3327393

[76] Segal E,Koller D.A module map showing conditional activity of expression modules in cancer..Nat Genet2004;36:1090-8 PMCID:PMC2271138

[77] Wong DJ,Ridky TW,Segal E.Module map of stem cell genes guides creation of epithelial cancer stem cells..Cell Stem Cell2008;2:333-44 PMCID:PMC2628721

[78] Nusse R,Cox D,Varmus H.Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15..Nature1984;307:131-6

[79] Mikhail S.Liver cancer stem cells..Int J Hepatol2011;2011:486954 PMCID:PMC3170823

[80] Salomon DS,Saeki T.Transforming growth factor-alpha: an oncodevelopmental growth factor..Cancer Cells1990;2:389-97

[81] Oishi N.Novel therapeutic strategies for targeting liver cancer stem cells..Int J Biol Sci2011;7:517-35 PMCID:PMC3088875

[82] Villanueva A.Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib..Clin Cancer Res2012;18:1824-6 PMCID:PMC3336075

[83] Morell CM.Notch signaling and new therapeutic options in liver disease..J Hepatol2014;60:885-90

[84] Zong Y.Molecular mechanisms of liver and bile duct development..Wiley Interdiscip Rev Dev Biol2012;1:643-55

[85] Gao J,Chen Y,Wang J.Deregulated expression of Notch receptors in human hepatocellular carcinoma..Dig Liver Dis2008;40:114-21

[86] Cadamuro M,Spirli C,Strazzabosco M.Autocrine and paracrine mechanisms promoting chemoresistance in cholangiocarcinoma..Int J Mol Sci2017;18: PMCID:PMC5297782

[87] Thayer SP,Heiser PW,Roberts DJ.Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis..Nature2003;425:851-6 PMCID:PMC3688051

[88] Liao X,Au CW,Chan HY.Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation..Carcinogenesis2009;30:131-40

[89] Oishi N,Kaneko S.Molecular biology of liver cancer stem cells..Liver Cancer2014;3:71-84 PMCID:PMC4057789

[90] Kango-Singh M.Regulation of organ size: insights from the Drosophila Hippo signaling pathway..Dev Dyn2009;238:1627-37

[91] Huang J,Barrera J,Pan D.The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP..Cell2005;122:421-34

[92] Lian I,Okazawa H,Zhao B.The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation..Genes Dev2010;24:1106-18 PMCID:PMC2878649

[93] Lu L,Kim SM,Liu P.Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver..Proc Natl Acad Sci U S A2010;107:1437-42 PMCID:PMC2824398

[94] Kim GJ,Park YN.Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma..PLoS One2013;8:e75449 PMCID:PMC3782432

[95] Lee KP,Kim TS,Park HD.The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis..Proc Natl Acad Sci U S A2010;107:8248-53 PMCID:PMC2889558

[96] Li J,Gores GJ,Mizuochi T.Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation..J Clin Invest2014;124:3241-51 PMCID:PMC4071370

[97] Stauffer JK,Andersen JB,Back TC.Coactivation of AKT and beta-catenin in mice rapidly induces formation of lipogenic liver tumors..Cancer Res2011;71:2718-27 PMCID:PMC3074499

[98] Lau CK,Fan ST.Role of stem cells in normal liver and cancer..Anticancer Agents Med Chem2011;11:522-8

[99] Zhang XL,Lv L,Gao J.Tumorspheres derived from HCC cells are enriched with cancer stem cell-like cells and present high chemoresistance dependent on the Akt pathway..Anticancer Agents Med Chem2015;15:755-63

[100] Feng X,Shi S,Zhou L.Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway..Int J Oncol2016;49:2600-10

[101] Shi DM,Qin CD.miR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by targeting PTEN via PI3K/Akt pathway..Onco Targets Ther2018;11:571-85 PMCID:PMC5790077

[102] Zhu M,Lu Y,Lin B.HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway..Int J Cancer2017;140:1346-55

[103] Xia H,Hui KM.MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer..Hepatology2013;58:629-41

[104] Zhang Y,Ding Y,Wang R.MiR-20a induces cell radioresistance by activating the PTEN/PI3K/Akt signaling pathway in hepatocellular carcinoma..Int J Radiat Oncol Biol Phys2015;92:1132-40

[105] Chiba T,Yuki K,Oshima M.Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners..PLoS One2014;9:e84807 PMCID:PMC3890271

[106] Galuppo R,Shah M,Chen C.Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/beta-catenin pathways..Anticancer Res2014;34:1709-13 PMCID:PMC5733784

[107] Zhang L,Li H,Zhao F.CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation..Sci Rep2016;6:27426 PMCID:PMC4891684

[108] Ding K,Gong D,Ji W.Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma..Biochem Biophys Res Commun2018;502:194-201

[109] Sato Y,Itatsu K,Kakuda Y.Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma..Am J Pathol2010;177:141-52 PMCID:PMC2893658

[110] Chan SL,Yeo W.Novel therapeutic targets and predictive markers for hepatocellular carcinoma..Expert Opin Ther Targets2015;19:973-83

[111] Chan LH,Ma S.Turning hepatic cancer stem cells inside out--a deeper understanding through multiple perspectives..Mol Cells2015;38:202-9 PMCID:PMC4363719

[112] Andersen JB.A perspective on molecular therapy in cholangiocarcinoma: present status and future directions..Future Medicine (Hepatic Oncology)2014;1:143-57 PMCID:PMC3997260

[113] Zhou B,Bailey ST,Jeong Y.Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal..J Clin Invest2014;124:553-63 PMCID:PMC3904607

[114] Cook AM,Ho Y,Stein A.Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells..Blood2014;123:2826-37 PMCID:PMC4007609

[115] Sherry MM,Wu JK.STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells..Stem Cells2009;27:2383-92 PMCID:PMC4391626

[116] Liu RY,Lei Z,Yang H.JAK/STAT3 signaling is required for TGF-beta-induced epithelial-mesenchymal transition in lung cancer cells..Int J Oncol2014;44:1643-51

[117] Rokavec M,Li H,Jiang L.IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis..J Clin Invest2014;124:1853-67 PMCID:PMC3973098

[118] Wang X,Shen W,Chen C.Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis..J Hepatol2016;64:1283-94

[119] Mitra A,Xia X,Chen J.IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition(+) metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficient beta2-spectrin(+/-) mice..Hepatology2017;65:1222-36 PMCID:PMC5360560

[120] Aljiffry M,Molinari M.Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009..World J Gastroenterol2009;15:4240-62 PMCID:PMC2744180

[121] Correnti M.Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer..Oncotarget2017;8:7094-115 PMCID:PMC5351693

[122] Qiu L,Fu S,Lu L.Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC..Oncol Lett2018;15:2039-48 PMCID:PMC5776936

[123] Chen J,Zhao J,Ying H.Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma..Cancer Lett2015;367:1-11

[124] Chow AK,Lam CS,Wan TM.The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance..PLoS One2013;8:e78675 PMCID:PMC3823841

[125] Zhang W,Wang WQ,Zhuang PY.Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice..Gastroenterology2012;143:1641-9 e5

[126] Hashimoto N,Yoshimura K,Hazama S.Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs..BMC Cancer2014;14:722 PMCID:PMC4190290

[127] Jang JW,Kim SH,Kim KM.CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma..Cancer Lett2017;389:1-10

[128] Oskarsson T,Massague J.Metastatic stem cells: sources, niches, and vital pathways..Cell Stem Cell2014;14:306-21 PMCID:PMC3998185

[129] Yang ZF,Ng MN,Yu WC.Significance of CD90(+) cancer stem cells in human liver cancer..Cancer Cell2008;13:153-66

[130] Yang ZF,Ho DW,Ng MNP.Identification of local and circulating cancer stem cells in human liver cancer..Hepatology2008;47:919-28

[131] Zhu L,Wang J.Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma..Tumour Biol2015;36:5353-60

[132] Liu S,Yu X,Cheng K.Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells..Gastroenterology2013;144:1031-41 e10

[133] Shuang ZY,Xu J,Liu YC.Transforming growth factor-beta1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma..Cancer Lett2014;354:320-8

[134] Lee D,Ryu J,Nam SH.Interaction of tetraspan(in) TM4SF5 with CD44 promotes self-renewal and circulating capacities of hepatocarcinoma cells..Hepatology2015;61:1978-97

[135] Nishiyama M,Yoshimura K,Matsukuma S.Metastatic ability and the epithelial-mesenchymal transition in induced cancer stem-like hepatoma cells..Cancer Sci2018;109:1101-9 PMCID:PMC5891178

[136] Gao Y,Liu W,Yang X.Knockdown of CD44 inhibits the invasion and metastasis of hepatocellular carcinoma both in vitro and in vivo by reversing epithelial-mesenchymal transition..Oncotarget2015;6:7828-37 PMCID:PMC4480719

[137] Yamashita T,Nakamoto Y,Nio K.Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma..Hepatology2013;57:1484-97

[138] Park NR,Jang JW,Jang B.Synergistic effects of CD44 and TGF-beta1 through AKT/GSK-3beta/beta-catenin signaling during epithelial-mesenchymal transition in liver cancer cells..Biochem Biophys Res Commun2016;477:568-74

[139] Warburg O.On the origin of cancer cells..Science1956;123:309-14

[140] Palorini R,Balestrieri C,Olivieri S.Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS..J Cell Biochem2014;115:368-79

[141] Mancini R,Pisanu ME,Maugeri-Sacca M.Metabolic features of cancer stem cells: the emerging role of lipid metabolism..Oncogene2018;37:2367-78

[142] Thanee M,Techasen A,Okazaki S.CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: a target for cholangiocarcinoma treatment..Cancer Sci2016;107:991-1000 PMCID:PMC4946726

[143] Song K,Han C,Dash S.Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122..Oncotarget2015;6:40822-35 PMCID:PMC4747371

[144] Hur W,Kim HU,Lee EB.Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133..Sci Rep2017;7:45557 PMCID:PMC5377334

[145] Chen CL,Punj V,Sher L.NANOG metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism..Cell Metab2016;23:206-19 PMCID:PMC4715587

[146] Ma MKF,Leung DHW,Ho NPY.Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation..J Hepatol2017;67:979-90

[147] Snyder V,Arnold L,Anant S.Cancer stem cell metabolism and potential therapeutic targets..Front Oncol2018;8:203 PMCID:PMC5996058

[148] Janzer A,Gonzalez-Herrera KN,Haigis MC.Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells..Proc Natl Acad Sci U S A2014;111:10574-9 PMCID:PMC4115496

[149] Martinez-Outschoorn UE,Pestell RG,Lisanti MP.Cancer metabolism: a therapeutic perspective..Nat Rev Clin Oncol2017;14:11-31

[150] Jayachandran A,Steel JC.Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma..J Hematol Oncol2016;9:74 PMCID:PMC5006452

[151] Suetsugu A,Aoki H,Kunisada T.Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells..Biochem Biophys Res Commun2006;351:820-4

[152] Rountree CB,He L.Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice..Stem Cells2009;27:290-9 PMCID:PMC2847372

[153] Agrawal S,Khoury T,Javle MM.CD24 expression is an independent prognostic marker in cholangiocarcinoma..J Gastrointest Surg2007;11:445-51 PMCID:PMC1852393

[154] Riener MO,Pestalozzi BC,Probst-Hensch N.Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract..Hum Pathol2010;41:1558-65

[155] Zhu Z,Yan M,Ge C.Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma..Int J Cancer2010;126:2067-78

[156] Yang W,Chen L,He YQ.Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells..Cancer Res2008;68:4287-95

[157] Ho DW,Yi K,Ng MN.Gene expression profiling of liver cancer stem cells by RNA-sequencing..PLoS One2012;7:e37159 PMCID:PMC3351419

[158] de Boer CJ,Janssen-van Rhijn CM.Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver..J Pathol1999;188:201-6

[159] Haraguchi N,Mimori K,Ohkuma M.CD13 is a therapeutic target in human liver cancer stem cells..J Clin Invest2010;120:3326-39 PMCID:PMC2929722

[160] Lee TK,Cheung VC,Ma S.CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation..Cell Stem Cell2011;9:50-63

[161] Lee TK,Lu P,Ma S.Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma..Hepatology2014;60:179-91

[162] Chiba T,Zheng YW,Saisho H.Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties..Hepatology2006;44:240-51

[163] Cao L,Jing W,Chen R.Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-kappaB-HIF-1alpha pathway..Oncotarget2015;6:6627-40 PMCID:PMC4466639

[164] Guo Z,Zhang J,Yang FQ.COX-2 promotes migration and invasion by the side population of cancer stem cell-like hepatocellular carcinoma cells..Medicine (Baltimore)2015;94:e1806 PMCID:PMC4915881

[165] Yang X,Qu S,Ruan B.MicroRNA-200a suppresses metastatic potential of side population cells in human hepatocellular carcinoma by decreasing ZEB2..Oncotarget2015;6:7918-29 PMCID:PMC4480725

[166] Ma S,Lee TK,Wo JY.Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations..Mol Cancer Res2008;6:1146-53

[167] Carpentino JE,Appelman HD,Steindler DA.Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer..Cancer Res2009;69:8208-15 PMCID:PMC2776663

[168] Ginestier C,Charafe-Jauffret E,Dutcher J.ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome..Cell Stem Cell2007;1:555-67 PMCID:PMC2423808

[169] Li T,Mei Y,Leng B.ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome..Lab Invest2010;90:234-44 PMCID:PMC3552330

[170] Cardinale V,Carpino G,Bragazzi MC.Profiles of cancer stem cell subpopulations in cholangiocarcinomas..Am J Pathol2015;185:1724-39 PMCID:PMC4450332

[171] Cao L,Zhai B,Xu W.Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines..BMC Gastroenterol2011;11:71 PMCID:PMC3136412

[172] Hanahan D.Accessories to the crime: functions of cells recruited to the tumor microenvironment..Cancer Cell2012;21:309-22

[173] Jinushi M,Yoshiyama H,Kinoshita I.Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells..Proc Natl Acad Sci U S A2011;108:12425-30 PMCID:PMC3145680

[174] Lu H,Tam WL,Ye X.A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages..Nat Cell Biol2014;16:1105-17 PMCID:PMC4296514

[175] Su S,Chen J,He C.A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis..Cancer Cell2014;25:605-20

[176] Wan S,Kryczek I,Sadovskaya A.Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells..Gastroenterology2014;147:1393-404 PMCID:PMC4253315

[177] Zhou W,Huang Z,Fang X.Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth..Nat Cell Biol2015;17:170-82 PMCID:PMC4312504